Search results for "Pentamidine"

showing 5 items of 5 documents

Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction

2015

Up to 80% of individuals with myotonic dystrophy type 1 (DM1) will develop cardiac abnormalities at some point during the progression of their disease, the most common of which is heart blockage of varying degrees. Such blockage is characterized by conduction defects and supraventricular and ventricular tachycardia, and carries a high risk of sudden cardiac death. Despite its importance, very few animal model studies have focused on the heart dysfunction in DM1. Here, we describe the characterization of the heart phenotype in a Drosophila model expressing pure expanded CUG repeats under the control of the cardiomyocyte-specific driver GMH5-Gal4. Morphologically, expression of 250 CUG repeat…

[SDV]Life Sciences [q-bio]Myotonic dystrophyMedicine (miscellaneous)lcsh:MedicineVentricular tachycardiaImmunology and Microbiology (miscellaneous)DiastoleHeart RateDrosophila ProteinsMyocytes CardiacGeneticsbiologyRNuclear ProteinsHeartPhenotype3. Good healthCell biology[SDV] Life Sciences [q-bio]Drosophila melanogasterPhenotypeDrosophilaDrosophila melanogasterDrosophila ProteinResearch Articlelcsh:RB1-214congenital hereditary and neonatal diseases and abnormalitiesSystoleLongevityNeuroscience (miscellaneous)In situ hybridizationMyotonic dystrophyGeneral Biochemistry Genetics and Molecular BiologyMuscleblindContractilitymedicinelcsh:PathologyAnimalsPentamidineHeart dysfunctionfungilcsh:RArrhythmias Cardiacbiology.organism_classificationmedicine.diseaseMyocardial ContractionSurvival AnalysisDisease Models AnimalTrinucleotide repeat expansionTrinucleotide Repeat Expansion
researchProduct

“Click” on PLGA-PEG and hyaluronic acid: Gaining access to anti-leishmanial pentamidine bioconjugates

2017

Pentamidine (Pent), an antiparasitic drug used for the treatment of visceral leishmaniasis, has been modified with terminal azide groups and conjugated to two different polymer backbones (PLGA-PEG [PP] copolymer and hyaluronic acid [HA]) armed with alkyne end-groups. The conjugation has been performed by Copper Catalyzed Azido Alkyne Cycloaddition (CuAAC) using CuSO4 /sodium ascorbate as metal source. The novel PP-Pent and HA-Pent bioconjugates are proposed, respectively, as non-targeted and targeted drug delivery systems against Leishmania infections. Moreover, Pent has been encapsulated into PP nanoparticles by the oil-in-water emulsion method, with the aim to compare the biological activ…

chemistry.chemical_classificationMaterials sciencebiologyBiomedical EngineeringAlkyneBiological activity02 engineering and technologyConjugated system010402 general chemistry021001 nanoscience & nanotechnologybiology.organism_classification01 natural sciencesCombinatorial chemistry0104 chemical sciencesBiomaterialschemistry.chemical_compoundchemistryTargeted drug deliveryHyaluronic acidmedicineAzideLeishmania infantum0210 nano-technologyPentamidinemedicine.drugJournal of Biomedical Materials Research Part B: Applied Biomaterials
researchProduct

"Click" on PLGA-PEG and hyaluronic acid: gaining access to anti-leishmanial pentamidine bioconjugates

2018

Pentamidine (Pent), an antiparasitic drug used for the treatment of visceral leishmaniasis, has been modified with terminal azide groups and conjugated to two different polymer backbones (PLGA-PEG [PP] copolymer and hyaluronic acid [HA]) armed with alkyne end-groups. The conjugation has been performed by Copper Catalyzed Azido Alkyne Cycloaddition (CuAAC) using CuSO4/sodium ascorbate as metal source. The novel PP-Pent and HA-Pent bioconjugates are proposed, respectively, as non-targeted and targeted drug delivery systems against Leishmania infections. Moreover, Pent has been encapsulated into PP nanoparticles by the oil-in-water emulsion method, with the aim to compare the biological activi…

drug delivery systems polymer Leishmaniasis biocompatibilityLeishmaniasipolymerAntiprotozoal AgentsPolyethylene GlycolsLeishmaniasis; biocompatibility; drug delivery systems; polymerdrug delivery systemsbiocompatibilityPolylactic Acid-Polyglycolic Acid Copolymerdrug delivery systems; polymer; Leishmaniasis; biocompatibilitydrug delivery systemClick ChemistryHyaluronic AcidLeishmania infantumLeishmaniasisPentamidine
researchProduct

Search of Chemical Scaffolds for Novel Antituberculosis Agents

2005

3 A method to identify chemical scaffolds potentially active against Mycobacterium tuberculosis is presented. The molecular features of a set of structurally heterogeneous antituberculosis drugs were coded by means of structural invariants. Three tech- niques were used to obtain equations able to model the antituberculosis activity: linear discriminant analysis, multilinear re- gression, and shrinkage estimation-ridge regression. The model obtained was statistically validated through leave-n-out test, and an external set and was applied to a database for the search of new active agents. The selected compounds were assayed in vitro, and among those identified as active stand reserpine, N,N,N…

0301 basic medicineStereochemistryAntitubercular AgentsQuantitative Structure-Activity RelationshipComputational biology01 natural sciencesBiochemistryAnalytical ChemistryMycobacterium tuberculosis03 medical and health sciencesmedicineComputer SimulationMycobacterium avium complexEthambutolVirtual screeningMolecular StructurebiologyChemistrybiology.organism_classificationLinear discriminant analysis0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyModels ChemicalDrug DesignRegression AnalysisMolecular MedicineMultiple linear regression analysisBiotechnologyPentamidinemedicine.drugSLAS Discovery
researchProduct

A Hyaluronic acid-pentamidine bioconjugate as macrophage mediated drug targeting delivery system for the treatment of Leishmaniasis

2015

Leishmaniasis is still a serious public health problem worldwide, especially in tropical areas where this infectious disease is endemic. The most severe form of the disease (i.e. visceral) can claim victims if left untreated and the few accessible drugs have several drawbacks including major side effects and parenteral administration. In this context, the investigation of new delivery modalities which might reduce the toxicity and increase the bioavailability of the drugs currently on the market represents a valid strategy to counter these problems. Herein we present the development of a macrophage mediated drug targeting delivery system by conjugating the anti-leishmanial drug pentamidine …

Drugbiologybusiness.industryGeneral Chemical Engineeringmedia_common.quotation_subjectLeishmaniasisGeneral ChemistryPharmacologymedicine.diseasebiology.organism_classificationchemistry.chemical_compoundchemistryTargeted drug deliveryInfectious disease (medical specialty)Hyaluronic acidMedicinePotencyLeishmania majorAMPHOTERICIN-B RESISTANCE DISCOVERY TOXICITY MICELLESbusinessPentamidinemedicine.drugmedia_common
researchProduct